Find Funding Opportunities

- The participating institutes of the National Institutes of Health invite the small business community to apply cutting edge-technology to develop new approaches and chemical modifications that will increase the long term stability, delivery and targeting of siRNAs in cells and tissues for laboratory and therapeutic applications. - The number of awards made under this solicitation will depend on the overall scientific merit of the applications and the availability of funds. - This PA uses the SBIR and STTR mechanisms. - Only small business concerns are eligible to submit applications. - Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. On an SBIR application, the principal investigator must have his/her primary employment (more than 50%) with the small business at the time of award and for the duration of the project. The PI on an STTR application may be employed with the small business concern or the participating non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant small business concern, which is characterized by an official relationship between the small business concern and that individual. - The NIH will accept as many "different" applications as the applicant organization chooses. - Application materials can be obtained at http://grants.nih.gov/grants/funding/sbir.htm. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088

- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung, and Blood Institute (NHLBI) encourage investigator-initiated research grant applications for projects studying pathogenesis and therapies for the muscular dystrophies. Responses to this announcement may include basic, translational or patient-oriented studies of Duchenne/Becker muscular dystrophy, facioscapulohumeral dystrophy, myotonic dystrophy or other forms of muscular dystrophy. - This PA will use the NIH Exploratory/Developmental Research Grant Award (R21) and the NIH Research Project Grant Award (R01) mechanisms. R21 applications may request up to $275,000 direct costs for the two-year term of the grant. There is no cost limit for the R01 mechanism, however applicants requesting $500,000 or more in direct costs for any year must obtain an agreement that one of the participating institutes will accept your application for consideration for review and possible award. To obtain this agreement, contact the appropriate IC program staff (listed in Section VII. below) at least 6 weeks prior to the application receipt date (8 weeks for NICHD and approximately 18 weeks for NIAMS). Please refer to NIAMS policy on applications requesting $500,000 or more per year in direct costs http://www.niams.nih.gov/rtac/grantapps/guidelines.htm. - The number of awards and the total amount to be awarded will depend on the number and quality of the applications received and the Institutes' availability of funds. - Eligible organizations include for-profit and non-profit organizations, public or private institutions such as universities, colleges, hospitals and laboratories, units of State and local governments, eligible agencies of the Federal government, domestic or foreign institutions/organizations. - Eligible principal investigators include any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. - There is no limit on the number of scientifically different applications that may be submitted. - Application materials and instructions are available at: http://grants.nih.gov/grants/funding/phs398/phs398.html - Telecommunications for the hearing impaired is available at: TTY 301-451-0088

The Office of Research on Women's Health (ORWH) and cosponsoring Institutes and Offices (IC) of the National Institutes of Health (NIH) invite submission of investigator-initiated research grant applications to support research on the epidemiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS) in diverse groups and across the life span.

- The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Arthritis and Skin Diseases (NIAMS) encourage submission of investigator-initiated research grant applications to study restless legs syndrome (RLS) and periodic limb movement disorder. - The total amount to be awarded will depend on the number and type of applications received and on their scientific merit. Specific funds are not set-aside for this program. - The anticipated number of awards is not known. The number of individual awards will depend on the number and scientific merit of the applications received. - The type of mechanism to be used is the Research Project (R01) mechanism. - Eligible organizations include for-profit or non-profit domestic public or private institutions, units of state or local governments, eligible agencies of the Federal government, and foreign institutions. - Eligible principal investigators include any individual with the skills, knowledge and resources necessary to carry out the proposed research. - There is no limit on the number of different applications from an institution or individual.

The goal of this Request for Applications (RFA) is to solicit applications to identify specific genes and gene variants in localized chromosomal regions that confer susceptibility to autism. Fine mapping of disease loci, or quantitative trait loci (QTLs), is expected to occur in very large datasets of pre-existing samples that have high statistical power for fine mapping autism susceptibility loci. In order to improve the probability of obtaining biologically and clinically meaningful associations between genotypes and disease outcomes, this initiative will not be limited to fine-scale mapping of a disease locus but will proceed to the next level of positional identification of strong candidate genes via assessment of the functional significance of the autism - associated genetic variants. Such assessments should include approaches based on computational biology, comparative and evolutionary genomics, as well as experimental evidence from relevant in vitro or animal model studies designed to probe the effect of genetic variants on gene expression, splicing or function.Applications are encouraged to focus on complex modes of inheritance that include multiple risk factors, e.g., environmental, multigenic and epigenetic effects. New data collection activities will not be supported. Data - and biomaterials, if possible - analyzed in projects supported under this RFA can be included in a data management and cell repository facility maintained under the NIMH Human Genetics Initiative (http://nimhgenetics.org) and broadly distributed to the scientific community.

- The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the National Institute of Mental Health (NIMH), the International Rett Syndrome Association (IRSA) and the Rett Syndrome Research Foundation (RSRF) invite research grant applications aimed at understanding and/or treating Rett Syndrome (RTT). The recent demonstration that mutations in the MECP2 gene cause most cases of RTT has created new opportunities for both basic and clinical research. Included within the scope of this Program Announcement with set-aside funds (PAS) are developmental, neuroanatomical, molecular genetic, and pathophysiological research, therapy development projects and clinical studies. Studies of the role of MeCP2 in basic biological processes or in the etiology of other neurological or neurobehavioral disorders are also appropriate. - The participating organizations intend to commit a total of $2,600,000 to this PAS in addition to funds available for applications sent in response to this initiative that score within the paylines of the participating NIH Institutes. - Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. - This PAS will use the NIH R01, R21 and R03 mechanisms. - Eligible organizations include: for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; eligible agencies of the Federal government; and domestic or foreign institutions/organizations. - Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - There is no limit to the number of applications each applicant may submit. - The PHS 398 application materials are available at http://grants.nih.gov/grants/funding/phs398/phs398.html.

In 1999, at the direction of Congress, the National Institute on Aging (NIA), in conjunction with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) embarked on the Alzheimer's Disease (AD) Prevention Initiative. An important part of the AD Prevention Initiative is to quicken the pace for translating basic science findings into clinical trials to evaluate treatment and prevention strategies. This Program Announcement (PA) focuses on AD drug discovery while a companion PA is targeted to AD pilot clinical trials.

The NIH hereby notifies Principal Investigators holding specific types of NIH research grants (listed in the full announcement) that funds are available for administrative supplements to improve the diversity of the research workforce by supporting and recruiting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented. Although the administrative supplements supported under this program provide funding for less than one percent of all individuals involved in NIH supported research, the NIH has found these awards to be an effective means of encouraging institutions to recruit from currently underrepresented groups. Administrative supplements must support work within the scope of the original project.

-The purpose of this RFA is to enhance our understanding of the effects of Type 1 diabetes on the development of new blood vessels from preexisting vessels (angiogenesis), in order to open new therapeutic avenues to treat diabetic vasculopathies. This RFA seeks basic and clinical studies on the mechanisms of abnormal angiogenesis seen in the complications of diabetes in wound healing, nephropathy, neuropathy and peripheral, coronary and cerebral arterial diseases. -Applications are invited from multiple investigators conducting collaborative research projects that foster sharing of expertise between the angiogenesis and diabetes fields. -The participating institutes plan on contributing $3 million to fund 5-10 new R01 awards with project periods ranging from 2-4 years. -Non-profit or for-profit organizations are eligible, including public or private institutions and domestic and foreign institutions. -Investigators may submit more than one application as part of different collaborative groups. There should be no scientific or budgetary overlap. -The PHS 398 application can be obtained from http://grants.nih.gov/grants/funding/phs398/phs398.html -Telecommunications for the hearing impaired is available at: TTY 301-451-0088

This Program Announcement with set-aside funds (PAS) invites applications proposing clinical and translational research in multiple sclerosis (MS) and targeting the neurodegenerative aspect of this disease. It is not intended to solicit proposals in basic neuroscience or glial biology. Rather, applications responsive to this PAS will apply ideas, insights, and discoveries generated through basic scientific inquiry to the treatment of MS and will have an emphasis on activities directly focused on the development of neuroprotective and regenerative therapies for MS. Applications testing novel therapeutic interventions in animal models or in in vitro systems are encouraged as are applications for the development of technologies that would facilitate the monitoring of their efficacy. Clinical trials and interventions in MS patients are not covered by this PAS and applicants are directed to instead use the funding mechanisms and opportunities listed at http://www.ninds.nih.gov/funding/areas/clinical_trials/index.htm.